Gilead's lenacapavir, effective in preventing HIV infections with a twice-yearly shot, seeks approval for preventive use. The drug's success in clinical trials, availability in poor countries, and its potential to curb the epidemic are discussed, alongside concerns over its exclusion from Latin America.
The drug lenacapavir, already used to treat HIV , is showing promise for prevention. Gilead aims to secure approval soon for its use in guarding against new infections. Clinical trials have demonstrated a 100% success rate in women and nearly equivalent efficacy in men. Gilead plans to permit generic versions in 120 poor nations with high HIV prevalence but has omitted Latin American countries, causing concerns.
UNAIDS highlights the unprecedented effectiveness of the drug and urges its widespread adoption, especially in at-risk regions
HIV Prevention Gilead Lenacapavir UNAIDS Generic Drugs
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Gilead's Lenacapavir Shows Promise in Preventing HIV InfectionsDrugmaker Gilead is seeking approval for its HIV medication, lenacapavir (Sunlenca), as a preventive measure. The drug has shown 100% effectiveness in women and near-perfect results in men. Gilead will make cheaper generic versions available in 120 poor countries, but its exclusion from Latin America could hinder progress.
Read more »
Gilead's HIV Prevention Shot Shows Near 100% Effectiveness, But Accessibility Concerns PersistGilead Sciences plans to seek approval for its HIV prevention drug, with a study indicating near 100% effectiveness in preventing HIV infections. The drugmaker will allow generic versions to be sold in 120 low-income countries, but has excluded most of Latin America, sparking concerns over missed prevention opportunities.
Read more »
Gilead's HIV Prevention Drug Shows Promise, But Global Access Remains In QuestionGilead Sciences Inc. aims to use lenacapavir as an HIV prevention tool, showing significant efficacy in studies. The drug's availability in 120 poor countries is welcomed, but its exclusion from most of Latin America raises concerns.
Read more »
How a $115M Crypto Fund With Big Ambitions Plans to Invest In Latin AmericaTom Carreras is a markets reporter for CoinDesk. He holds BTC, ETH and SOL above CoinDesk's disclosure threshold of $1,000.
Read more »
Trump looms large as Biden set to meet China's Xi during Latin America summitsPresident Biden is in Latin America for the APEC and G-20 summits, in what is likely his last trip as president. The back-to-back summits come as an impending second Trump presidency is near, which may rattle some world leaders.
Read more »
A New Corporate Playbook for Navigating Political Uncertainty in Latin AmericaAlliances with national governments are no longer enough.
Read more »